Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer
about
Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors.MAEL contributes to gastric cancer progression by promoting ILKAP degradation.Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
P2860
Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chk1 inhibition potentiates th ...... bitor BMN673 in gastric cancer
@en
Chk1 inhibition potentiates th ...... itor BMN673 in gastric cancer.
@nl
type
label
Chk1 inhibition potentiates th ...... bitor BMN673 in gastric cancer
@en
Chk1 inhibition potentiates th ...... itor BMN673 in gastric cancer.
@nl
prefLabel
Chk1 inhibition potentiates th ...... bitor BMN673 in gastric cancer
@en
Chk1 inhibition potentiates th ...... itor BMN673 in gastric cancer.
@nl
P2093
P2860
P1476
Chk1 inhibition potentiates th ...... bitor BMN673 in gastric cancer
@en
P2093
Gengchen Xie
Gordon B Mills
Guang Peng
Jaffer Ajani
Jianying Chen
Kaixiong Tao
Lihong Zhang
Peng Zhang
Prabodh Kapoor
P2860
P304
P577
2017-03-01T00:00:00Z